Canada's Bausch Health Q3 revenue beats estimates on Salix, Solta demand
BHC•Bausch Health's Q3 revenue rose 10% year over year to $2.94 billion, beating the $2.76 billion consensus, while adjusted EPS increased 53%. The company raised its 2026 revenue guidance to $10.975 billion-$11.175 billion and adjusted EBITDA guidance to $4.315 billion-$4.415 billion.
1. Quarterly results
Bausch Health reported Q3 revenue of $2.94 billion, up 10% year over year and above the $2.76 billion consensus estimate. Net income was $446 million and operating income was $983 million; adjusted EPS rose 53% year over year.
2. Raised 2026 outlook
The company raised its 2026 revenue guidance to $10.975 billion-$11.175 billion and its adjusted EBITDA outlook to $4.315 billion-$4.415 billion. It expects adjusted cash flows from operations of $1.6 billion-$1.675 billion and said tariff uncertainty may affect 2026 results.
3. Business drivers
Salix segment growth was led by Xifaxan, whose revenue rose 16%. Solta Medical segment growth was aided by the acquisition of a distributor in China, offsetting an organic decline in Asia Pacific, while diversified segment organic revenue increased primarily on double-digit growth in Dermatology.
